Experimental resistance to drug combinations in Leishmania donovani: metabolic and phenotypic adaptations.

ABSTRACT: Together with vector control, chemotherapy is an essential tool for the control of visceral leishmaniasis (VL), but its efficacy is jeopardized by growing resistance and treatment failure against first-line drugs. To delay the emergence of resistance, the use of drug combinations of existing antileishmanial agents has been tested systematically in clinical trials for the treatment of visceral leishmaniasis (VL). In vitro, Leishmania donovani promastigotes are able to develop experimental resistance to several combinations of different antileishmanial drugs after 10 weeks of drug pressure. Using an untargeted liquid chromatography-mass spectrometry (LC-MS) metabolomics approach, we identified metabolic changes in lines that were experimentally resistant to drug combinations and their respec

SUBMITTER: Berg M 

PROVIDER: S-EPMC4356759 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature